Differential Effects in Cardiovascular Markers between High-Dose Angiotensin II Receptor Blocker Monotherapy and Combination Therapy of ARB with Calcium Channel Blocker in Hypertension (DEAR Trial)

Table 3

Effects of percent changes in LDL-C, plasma aldosterone, ABI, AI, clinical BP, 24-h BP, daytime BP, and nighttime BP on percent changes in CAVI after combination therapy.

ANCOVA	Coefficient	SE	t-value	P
Intercept	−17.930	9.220	−1.945	.0696
ΔLDL	0.547	10.422	0.052	.9588
Intercept	−48.479	26.262	−1.846	.0878
Δplasma aldosterone	30.080	27.760	1.084	.2982
Intercept	−0.061	0.021	−2.893	.0106
ΔABI	−0.052	0.024	−0.479	.0441
Intercept	−7.475	3.985	−1.876	.0852
ΔAI	−1.744	4.932	−0.354	.7298
Intercept	−8.027	7.571	−1.060	.3048
Δclinic SBP	21.792	8.558	2.546	.0216
Intercept	−10.428	4.509	−2.313	.0344
Δclinic DBP	6.750	5.096	1.325	.2039
Intercept	−7.595	4.425	−1.717	.1066
▵24h SBP	8.584	4.896	1.753	.1000
Intercept	−8.952	3.175	−2.819	.0129
Δ24h DBP	1.042	3.513	0.297	.7708
Intercept	−9.199	4.478	−2.054	.0578
Δdaytime SBP	6.761	4.955	1.364	.1926
Intercept	−9.811	3.172	−3.093	.0074
Δdaytime DBP	−0.711	3.509	−0.203	.8422
Intercept	−6.706	4.743	−1.414	.1778
Δnighttime SBP	9.909	5.248	1.888	.0785
Intercept	−7.240	3.250	−2.228	.0416
Δnighttime DBP	5.993	3.596	1.666	.1164

LDL-C, low-density lipoprotein cholesterol; ABI, ankle-brachial index; AI: augmentation index; BP: blood pressure; CAVI: cardioankle vascular index; ANCOVA: analysis of covariance; SE: standard error.